Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Rating of “Moderate Buy” from Analysts

Editas Medicine, Inc. (NASDAQ:EDIT) has been assigned a consensus recommendation of “Moderate Buy” from the eight research firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $5.30.

Several brokerages recently commented on EDIT. Chardan Capital reiterated a “buy” rating and set a $3.50 price target on shares of Editas Medicine in a research note on Monday, March 9th. JonesTrading upgraded Editas Medicine from a “hold” rating to a “buy” rating and set a $8.00 target price on the stock in a research report on Tuesday, March 10th. TD Cowen reissued a “buy” rating on shares of Editas Medicine in a research report on Monday, March 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Editas Medicine in a research report on Wednesday, January 21st. Finally, Robert W. Baird set a $6.00 price objective on Editas Medicine in a research note on Monday, March 9th.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of EDIT. Captrust Financial Advisors acquired a new stake in shares of Editas Medicine during the second quarter worth about $26,000. StoneX Group Inc. acquired a new stake in Editas Medicine during the 4th quarter worth approximately $33,000. Victory Capital Management Inc. purchased a new position in shares of Editas Medicine in the 3rd quarter valued at approximately $36,000. Sei Investments Co. acquired a new position in Editas Medicine in the 3rd quarter valued at $46,000. Finally, Baader Bank Aktiengesellschaft acquired a new position in Editas Medicine in the 3rd quarter valued at $50,000. 71.90% of the stock is currently owned by institutional investors and hedge funds.

Editas Medicine Stock Performance

NASDAQ:EDIT opened at $2.32 on Thursday. Editas Medicine has a 1 year low of $0.91 and a 1 year high of $4.54. The stock has a market cap of $227.06 million, a P/E ratio of -1.23 and a beta of 2.16. The stock has a 50-day simple moving average of $2.09 and a 200-day simple moving average of $2.56.

Editas Medicine (NASDAQ:EDIT) last posted its earnings results on Monday, March 9th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.21. Editas Medicine had a negative return on equity of 389.73% and a negative net margin of 395.02%.The firm had revenue of $24.74 million during the quarter, compared to analysts’ expectations of $8.77 million. On average, equities research analysts predict that Editas Medicine will post -2.71 EPS for the current year.

Key Editas Medicine News

Here are the key news stories impacting Editas Medicine this week:

• Positive Sentiment: Zacks raised several forward estimates, including Q4 2026 (from -$0.37 to -$0.34), Q3 2026 (from -$0.36 to -$0.35), FY2026 (from -$1.41 to -$1.38) and FY2027 (from -$1.37 to -$1.36) — these revisions reduce expected future losses and may support the stock. Source
• Positive Sentiment: Zacks also raised near-term quarterly estimates for Q1 2027 (from -$0.36 to -$0.35) and Q2 2027 (from -$0.35 to -$0.34), which signals modest model improvement into 2027. Source
• Neutral Sentiment: Zacks published a new FY2028 EPS projection of -$1.34 for Editas; as a first-look estimate this provides a baseline but limited immediate market impact until detail or conviction increases. Source
• Neutral Sentiment: Multiple short-interest updates reported a “significant increase” but show zero shares and NaN changes in the data — the figures look erroneous/ambiguous, so short-interest-driven pressure is unclear for now. Traders should treat these reports cautiously. Source
• Negative Sentiment: Zacks trimmed Q2 2026 EPS (from -$0.33 to -$0.34) and Q4 2027 EPS (from -$0.32 to -$0.33) in separate notes — small but downward adjustments that marginally increase near-term expected losses. Source

Editas Medicine Company Profile

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.